Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.

Runze ShangXinhua SongPan WangYi ZhouXinjun LuJingxiao WangMeng XuXinyan ChenKirsten UtpatelLi CheBinyong LiangAntonio CiglianoMatthias EvertDiego F CalvisiXin Chen

Published in: Gut (2020)

c-MET/ERK/p21/PKM2 cascade and VEGFR2-induced angiogenesis are the primary targets of cabozantinib in HCC treatment. Combination therapies with cabozantinib and mTOR inhibitors may be effective against human HCC.

Keyphrases

endothelial cells
cell proliferation
signaling pathway
metastatic renal cell carcinoma
combination therapy
diabetic rats
drug induced
stress induced